This PowerPoint presentation has great suggestions and tips on how to handle a night on call. It is specially useful for junior physicians and covers real-life clinical situations you may encounter.
EMEA didn’t approve treatment of fibromyalgia as a new indication for pregabalin (Lyrica).The CHMP was concerned that the benefits of Lyrica in fibromyalgia had not been shown in either the short or the long term.
According to a press release, the Scottish Medicines Consortium (SMC) did not accept aripiprazole for the treatment of manic episodes in bipolar I disorder and for the prevention of new manic episodes. According to the SMC, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance. Psychiatrist Daniel Carlat from “The Carlat […]
Agomelatine (Valdoxan, Melitor, Thymanax) is a recently marketed new drug for the treatment of major depression with a novel mechanism of action. It can be included in the class of “other antidepressants”, or classified as a melatonergic drug. Mechanism of action Agomelatine acts as an agonist on melatonin MT1 and MT2 receptors. Additionally, it blocks […]
Video: patient safety warning on chronic use of metoclopramide and the risk of developing tardive dyskinesia.
PowerPoint slideshows on pharmacology of antiemetics .MOA, dosing, indications and side effects of: serotonin and dopamine antagonists, anticholinergics, new antiemetics.
PowerPoint lectures on antidepressants pharmacology. MOA, pharmacokinetics, indications, and side effects of: tryciclics, SSRIs, heterocyclics, MAO inhibitors.
Essential Evidence Plus, formerly InfoPOEMs is a service by John Wiley and Sons that aims to give physicians succinct medical evidence that will impact in their medical practice. In this podcast Dr. Ebell and Dr. Wilkes (National Public Radio) discuss the POEM titled: “Antidepressants only modestly effective for adolescent depression” Listen to the podcast on […]
The manufacturer of carbamazepine (Tegretol) updated the drug’s summary of product characteristics: ‘Before deciding to initiate treatment, patients of Han Chinese and Thai origin should whenever possible be screened for HLA-B*1502 as this allele strongly predicts the risk of severe carbamazepine-associated Stevens-Johnson syndrome’ Health Canada warned in March 2008 about carbamazepine’s side effects in […]
The National Prescribing Service Limited (Australia) made an independent evaluation on the role of desvenlafaxine (Pristiq) for the treatment of major depressive disorder. Summary: Desvenlafaxine is the active metabolite of venlafaxine. There is no evidence that desvenlafaxine is more effective, safer or better tolerated than venlafaxine or other antidepressants. Doses above 50 mg/day are unlikely […]
MCQs for USMLE review on psychopharmacology: antipsychotics, benzodiazepines, antidepressants and lithium
These pharmacology MCQs from the UMKC School of Medicine have a different degree of difficulty, but are useful to review pharmacology of psychotropics. Psychotropics Item Number: 11667 correct answer: 4 category: Psychotropics 1. The symptoms of tardive dyskinesia will acutely improve with: 1. administration of diphenhydramine 2. administration of amantadine 3. administration of bromocriptine 4. […]
Essential Evidence Plus, formerly InfoPOEMs is a service by John Wiley and Sons that aims to give physicians succinct medical evidence that will impact in their medical practice. In this podcast Dr. Ebell and Dr. Wilkes (National Public Radio) discuss the POEM that analyzes the ACP guidelines (published in Annals of Internal Medicine) on antidepressants. […]
I would like to recommend Pharmamotion readers one of the most popular articles in PLoS Medicine: Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature. Jeffrey R. Lacasse, Jonathan Leo The article is a definitely a must read for those interested in direct-to-consumer advertising (DTCA) issues. However,for those who don’t have enough […]
The FDA issued an alert (February 23, 2009) about the risk of metabolic acidosis in patients treated with zonisamide (Zonegran). An excerpt from the alert on this anticonvulsant adverse effect: Following a review of updated clinical data, the FDA has determined that treatment with zonisamide can cause metabolic acidosis in some patients. Zonisamide is indicated […]